OptiNose joins the biotech IPO fiesta, raises $120M in upsized offering

A month after bagging an FDA approval of its drug/device for nasal polyps, OptiNose has taken advantage of a red-hot biotech IPO market to raise $120 million in an upsized offering.

The Yardley, PA-based biotech’s S-1 explains that it will use the cash to launch its new product into the ENT market, with plans to hire a 75-member specialty sales force to go after a target group of 15,000 doctors. And it will now go after a broader market, with trials planned for rhinosinusitis. It will list on Nasdaq as $OPTN.

OptiNose bumped up the offering from 6.3 million to 7.5 million shares, selling the stock at $16 a pop — right in the middle of the range.

Over the last few months the biotech IPO window has been wide open, with a string of debuts for startups that includes some stellar outings. And as more companies perform well, you can expect a steady string of new filings.

Jefferies and Piper Jaffray are acting as the lead joint book-running managers of the OptiNose offering. BMO Capital Markets and RBC Capital Markets are also acting as joint book-running managers for the offering. The underwriters have a 30-day option to purchase up to an additional 1,125,000 shares at $16.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->